13 - Leveraging Machine Learning to Infectious Diseases

Thursday, September 30, 2021

11:00 AM - 12:15 PM EDT

Moderator(s)

DJ

David Jenkins, MSc FRCPath

Consultant Medical Microbiologist
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom

Menarini (Individual(s) Involved: Self): Speakers' bureau; Pfizer (Individual(s) Involved: Self): Speakers' bureau; Shionogi (Individual(s) Involved: Self): Speakers' bureau
Truc Cecilia Tran, PharmD

Assistant Professor
UTHealth McGovern Medical School
Houston, Texas, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Speaker(s)

James Collins, PhD

Termeer Professor of Medical Engineering and Science
Biological Engineering
Massachusetts Institute of Technology
Cambridge, MA, United States

Enbiotix (Individual(s) Involved: Self): Advisor or Review Panel member, Shareholder; Sherlock Biosciences (Individual(s) Involved: Self): Board Member, Shareholder
Barbara Han, PhD

Disease Ecologist
Cary Institute of Ecosystem Studies
Millbrook, NY, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.
Jonathan Chen, MD, PhD

Assistant Professor
Stanford University
Stanford, CA, United States

National Institute of Drug Abuse Clinical Trials Network (Individual(s) Involved: Self): Consultant; Reaction Explorer (Individual(s) Involved: Self): Co-Founder, Other Financial or Material Support; Roche Inc (Individual(s) Involved: Self): Consultant; Tuoic Inc (Individual(s) Involved: Self): Consultant; Younker Hyde MacFarlane PLLC (Individual(s) Involved: Self): Consultant

Participants should be aware of the following financial/non-financial relationships:

David R. Jenkins, MSc FRCPath: Menarini (Individual(s) Involved: Self): Speakers' bureau; Pfizer (Individual(s) Involved: Self): Speakers' bureau; Shionogi (Individual(s) Involved: Self): Speakers' bureau

Truc Cecilia Tran, PharmD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

James Collins, PhD: Enbiotix (Individual(s) Involved: Self): Advisor or Review Panel member, Shareholder; Sherlock Biosciences (Individual(s) Involved: Self): Board Member, Shareholder

Barbara A. Han, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Jonathan H. Chen, MD, PhD: National Institute of Drug Abuse Clinical Trials Network (Individual(s) Involved: Self): Consultant; Reaction Explorer (Individual(s) Involved: Self): Co-Founder, Other Financial or Material Support; Roche Inc (Individual(s) Involved: Self): Consultant; Tuoic Inc (Individual(s) Involved: Self): Consultant; Younker Hyde MacFarlane PLLC (Individual(s) Involved: Self): Consultant

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

apply machine learning approaches to early antibiotic discovery
discuss machine learning as a clinical support tool for antimicrobial selection
use machine learning and computational tools to identify and monitor emerging infectious diseases

Presentations:

A Deep Learning Approach to Antibiotic Discovery
Speaker: James Collins, PhD – Massachusetts Institute of Technology
Artificial Intelligence and Emerging Infectious Diseases
Speaker: Barbara A. Han, PhD – Cary Institute of Ecosystem Studies
Machine-learning for Selection of Antibiotics
Speaker: Jonathan H. Chen, MD, PhD – Stanford University